Dihexa: hepatocyte growth factor signalling and synaptic potentiation

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, also designated PNB-0408) emerged from research at Washington State University into angiotensin IV analogues. Angiotensin IV — the hexapeptide fragment Ang(3-8) of the angiotensin cascade — was found to enhance memory consolidation and spatial learning in rodents in the 1990s, but its mechanism remained poorly characterised and its metabolic instability precluded therapeutic development.

Dihexa was designed as a metabolically stable analogue of Ang(3-8). When Joseph Harding and colleagues at WSU investigated its mechanism, they discovered it operated not through the AT4 receptor (as initially hypothesised for angiotensin IV) but through potentiation of hepatocyte growth factor (HGF) signalling at the MET receptor tyrosine kinase — a completely unexpected mechanism with major implications for synaptogenesis research.

HGF/MET pathway in the brain

Hepatocyte growth factor (HGF) and its receptor MET were originally characterised in the context of liver development and regeneration, but the pathway is expressed throughout the central nervous system and plays significant roles in neural development, neuroprotection, and synaptic plasticity.

In the adult brain, HGF/MET signalling:

• Promotes dendritic branching and spine density in hippocampal neurons
• Drives formation of new synaptic connections (synaptogenesis) — the cellular substrate of learning and memory consolidation
• Protects neurons from apoptosis following ischaemic or excitotoxic injury
• Modulates long-term potentiation (LTP) — the sustained synaptic strengthening that underlies memory encoding
• Supports neurogenesis in the hippocampal dentate gyrus

HGF levels decline with age in rodent and human brain tissue, and this decline correlates with reductions in synaptic density and cognitive function — establishing a plausible mechanistic link between reduced HGF/MET signalling and age-related cognitive decline.

Dihexa's mechanism: HGF potentiation

Dihexa does not act as a direct HGF mimetic. Instead, it acts as an allosteric potentiator: it binds to HGF and stabilises its interaction with the MET receptor, markedly increasing the sensitivity of the HGF/MET system to available endogenous HGF.

This potentiation mechanism means dihexa's effects depend on endogenous HGF being present — it amplifies an existing signal rather than creating a synthetic one. This has mechanistic implications: in tissues or conditions where endogenous HGF is depleted, dihexa's effect may be diminished.

The structural basis for this interaction involves dihexa binding to a region on HGF that facilitates the conformational change required for MET receptor dimerisation and kinase activation. This is distinct from how angiotensin IV peptides were previously understood to function.

Key preclinical findings

Spatial memory: In aged rats with documented spatial memory impairment, subcutaneous dihexa administration at doses of 1 mg/kg produced dramatic restoration of performance on Morris water maze testing — equivalent to performance of young adult controls. This effect persisted for weeks after dosing ended, suggesting structural synaptic changes rather than acute pharmacological effects (Benoist et al., Journal of Pharmacology and Experimental Therapeutics, 2011).

Potency: Harding and colleagues reported that dihexa was approximately 10 million times more potent than BDNF in inducing hippocampal synaptogenesis in a dendritic branching assay. This extraordinary potency claim has been influential but requires independent confirmation — it derives from a single research group's in vitro assay system, and the comparison to BDNF involves different measurement endpoints.

Synaptogenesis confirmation: Histological analysis showed dihexa-treated aged animals had significantly increased hippocampal synaptophysin staining (a presynaptic marker), confirming that the behavioural improvements were accompanied by measurable increases in synaptic density.

Alzheimer's model: In a transgenic Alzheimer's mouse model (APP/PS1), dihexa reduced amyloid plaque burden, improved synaptic density, and improved cognitive performance. The mechanisms proposed include both synaptogenesis and indirect effects on amyloid processing downstream of MET activation.

Depression model: Dihexa showed antidepressant-like effects in the forced swim test and tail suspension test in rodents, consistent with the known role of hippocampal neurogenesis and synaptic remodelling in antidepressant response.

Structural and pharmacological properties

Dihexa's design incorporates several modifications over native angiotensin IV that improve its research utility:

• N-hexanoyl modification: The N-terminal hexanoic acid chain significantly improves blood-brain barrier penetration compared to native peptides, allowing systemic administration to reach CNS targets
• C-terminal amidation: Protects against exopeptidase degradation, extending plasma half-life
• Metabolic stability: These modifications make dihexa substantially more CNS-bioavailable than native angiotensin IV, which cannot cross the blood-brain barrier effectively

Comparison with other synaptogenic compounds

The synaptogenesis research space includes several compounds with overlapping mechanisms:

BDNF/TrkB agonists: Brain-derived neurotrophic factor and its receptor TrkB are the most studied synaptogenesis pathway. BDNF itself has poor CNS bioavailability from systemic administration; small-molecule TrkB agonists are under development. Dihexa's claimed potency advantage over BDNF in synaptogenesis assays, if confirmed, would represent a meaningful differentiation.

Semax and BDNF upregulation: Semax (covered in the Semax and BDNF article) increases BDNF expression rather than directly potentiating its downstream signalling, representing a complementary mechanism at an upstream node.

Limitations of the evidence base

The dihexa literature has important limitations that must be acknowledged:

Single-group origin: The foundational mechanistic and in vivo efficacy data comes predominantly from the Harding laboratory at WSU. Independent replication of the key findings — particularly the synaptogenesis potency claim and the sustained memory restoration — has been limited in the published literature.

No clinical trials: No registered clinical trials of dihexa appear in ClinicalTrials.gov as of 2025. The compound has not progressed to human safety or efficacy studies through conventional pharmaceutical development pathways.

Mechanism complexity: HGF/MET signalling has pleiotropic effects across tissues. MET is overexpressed in numerous cancers and acts as a proto-oncogene in some contexts. Whether chronic HGF/MET potentiation in neural tissues carries oncogenic risk is not established — this represents a significant unknown for any long-term application.

Dose-response characterisation: Dose-response relationships for both efficacy and safety in rodent models were established in a limited range; the margins between cognitive effect doses and any adverse effect doses are not fully mapped.

Research context

Dihexa is classified as a research peptide. It is not approved by the TGA, FDA, or any other regulatory authority for human use. Its investigation sits within the broader cognitive enhancement and neuroprotection research space alongside compounds like Semax and Selank — peptides with CNS-active mechanisms that have preclinical data but lack the clinical trial evidence required for regulatory approval.

Summary

Dihexa's mechanism — potentiation of HGF/MET signalling at synaptic density-regulating pathways — is mechanistically distinctive from other cognitive enhancement research peptides. Preclinical data demonstrates dramatic synaptogenesis and memory restoration in aged rodents, with a potency advantage over direct BDNF supplementation claimed in dendritic branching assays. The evidence base is limited by single-group origin, absence of clinical trials, and unknowns around MET pathway oncogenic risk with chronic activation. It remains a subject of preclinical research interest rather than a clinically validated intervention.